Skip to main content

Table 1 Effects of CNX-011-67 on blood HbA1c, Fructosamine, PDX1 and apoptotic positive cells

From: Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats

Parameters

 

    Groupings

 

Lean control

ZDF control

CNX-011-67 (5 mg/kg)

HbA1c

3.84 ± 0.08

5.50 ± 0.30

5.18 ± 0.11

Fructosamine

92.47 ± 10.68

236.36 ± 19.08

111.25 ± 10.61**

HOMA-IR

2.16 ± 0.74

64.26 ± 6.18

41.82 ± 2.59*

HOMA-beta

117.34 ± 39.35

1520.20 ± 227.30

2206.79 ± 418.69

PDX1 positive cells

650 ± 49

461 ± 47.50

589 ± 43

Apoptotic cells

00 ± 00

47 ± 8.7

29 ± 4.6

  1. Data in all panels are mean ± SEM (n = 10/group). Statistical comparison was conducted by One-way ANOVA with Dunnett’s post test correction to arrive at the significance level when compared with ZDF control. (*p < 0.05 and **p < 0.01).
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us